Clinical Trials
5 trialsNCT03341936 2025-06-18
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03532451 2024-09-19
PrE0807
PrECOG, LLC.
Phase 1 Completed
NCT02481297 2020-05-28
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02599649 2020-01-14
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02399917 2019-09-24
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated